EPAS1 and nonpapillary renal cell carcinoma: However, certain VHL mutant ccRCC patients are resistant to inhibitors targeting the HIF2α signaling pathway, suggesting that VHL deficiency may influence the unidentified HIF2α-independent signaling pathways (Patel et al., 2022).